We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Altria Nicotine Pouch Volumes Surge: Is Helix the Real Profit Driver?
Read MoreHide Full Article
Key Takeaways
MO's shipped 42.2M on! cans in Q3, with nine-month volumes up 14.8% even as other oral categories declined.
Helix performance helped stabilize adjusted operating income and expand margins in the oral tobacco segment.
Altria saw on! prices rise 1.5% year over year, even as average nicotine pouch prices fell nationally.
Altria Group, Inc.’s ((MO - Free Report) ) nicotine pouch business, operated through Helix Innovations, is becoming a growing driver of the company’s oral tobacco segment. As traditional oral categories decline, nicotine pouches continue to gain momentum. In the third quarter of 2025, pouches were the fastest-growing part of the segment.
Helix shipped 42.2 million cans of on! in the third quarter. For the first nine months of 2025, shipments rose 14.8% to 133.6 million cans, significantly outperforming other oral tobacco categories and highlighting Helix’s expanding role in segment profitability.
What stands out is Helix’s contribution to earnings quality, not just volume. Its year-over-year performance helped stabilize adjusted operating income and expand margins, even as total segment volumes declined. Helix also recently launched on! PLUS in select states, offering multiple flavors and nicotine strengths, adding a premium, differentiated option that could further boost growth.
Pricing trends further highlight Helix’s position. While average nicotine pouch prices fell roughly 7% nationally, on! retail prices increased about 1.5% year over year in the third quarter. At the same time, on!’s retail share of total oral tobacco was 8.7%, unchanged sequentially and down 0.1 share point year over year, reflecting recent retail performance.
Overall, Helix’s results highlight how nicotine pouches are becoming a more visible part of MO’s oral tobacco business. As traditional oral categories continue to decline, Helix’s volume performance, pricing actions, and impact on margins help shape the segment’s current operating profile.
Where PM and TPB Stand Next to Altria
Philip Morris International Inc. ((PM - Free Report) ) showed strong momentum in its modern oral portfolio in the third quarter of 2025, with global ZYN can shipments rising about 36% and U.S. ZYN offtake growing 39%, according to Nielsen estimates. Philip Morris International noted that ZYN was fully available to the trade and supported by a wide range of commercial activities, including select short-term relaunch promotions following earlier supply constraints. Philip Morris International also emphasized continued investments in capacity and commercialization to support rising demand in the nicotine pouch segment.
Turning Point Brands, Inc. ((TPB - Free Report) ) delivered exceptionally strong modern oral growth in the third quarter of 2025, with segment net sales surging 627.6% year over year to $36.7 million, now representing 30.8% of the company’s revenues. Turning Point Brands highlighted sequential modern oral growth of 22% and raised its full-year modern oral sales outlook to $125-$130 million. Management also noted progress toward qualifying its first U.S. white-pouch production lines in 2026, underscoring Turning Point Brands’ growing presence in the nicotine pouch category.
Altria’s Price Performance, Valuation & Estimates
Shares of Altria have lost 0.8% in the past month against the industry’s growth of 1.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, MO trades at a forward price-to-earnings ratio of 10.36X, down from the industry’s average of 14.47X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MO’s 2025 and 2026 earnings implies year-over-year growth of 6.3% and 2.3%, respectively.
Image: Bigstock
Altria Nicotine Pouch Volumes Surge: Is Helix the Real Profit Driver?
Key Takeaways
Altria Group, Inc.’s ((MO - Free Report) ) nicotine pouch business, operated through Helix Innovations, is becoming a growing driver of the company’s oral tobacco segment. As traditional oral categories decline, nicotine pouches continue to gain momentum. In the third quarter of 2025, pouches were the fastest-growing part of the segment.
Helix shipped 42.2 million cans of on! in the third quarter. For the first nine months of 2025, shipments rose 14.8% to 133.6 million cans, significantly outperforming other oral tobacco categories and highlighting Helix’s expanding role in segment profitability.
What stands out is Helix’s contribution to earnings quality, not just volume. Its year-over-year performance helped stabilize adjusted operating income and expand margins, even as total segment volumes declined. Helix also recently launched on! PLUS in select states, offering multiple flavors and nicotine strengths, adding a premium, differentiated option that could further boost growth.
Pricing trends further highlight Helix’s position. While average nicotine pouch prices fell roughly 7% nationally, on! retail prices increased about 1.5% year over year in the third quarter. At the same time, on!’s retail share of total oral tobacco was 8.7%, unchanged sequentially and down 0.1 share point year over year, reflecting recent retail performance.
Overall, Helix’s results highlight how nicotine pouches are becoming a more visible part of MO’s oral tobacco business. As traditional oral categories continue to decline, Helix’s volume performance, pricing actions, and impact on margins help shape the segment’s current operating profile.
Where PM and TPB Stand Next to Altria
Philip Morris International Inc. ((PM - Free Report) ) showed strong momentum in its modern oral portfolio in the third quarter of 2025, with global ZYN can shipments rising about 36% and U.S. ZYN offtake growing 39%, according to Nielsen estimates. Philip Morris International noted that ZYN was fully available to the trade and supported by a wide range of commercial activities, including select short-term relaunch promotions following earlier supply constraints. Philip Morris International also emphasized continued investments in capacity and commercialization to support rising demand in the nicotine pouch segment.
Turning Point Brands, Inc. ((TPB - Free Report) ) delivered exceptionally strong modern oral growth in the third quarter of 2025, with segment net sales surging 627.6% year over year to $36.7 million, now representing 30.8% of the company’s revenues. Turning Point Brands highlighted sequential modern oral growth of 22% and raised its full-year modern oral sales outlook to $125-$130 million. Management also noted progress toward qualifying its first U.S. white-pouch production lines in 2026, underscoring Turning Point Brands’ growing presence in the nicotine pouch category.
Altria’s Price Performance, Valuation & Estimates
Shares of Altria have lost 0.8% in the past month against the industry’s growth of 1.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, MO trades at a forward price-to-earnings ratio of 10.36X, down from the industry’s average of 14.47X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MO’s 2025 and 2026 earnings implies year-over-year growth of 6.3% and 2.3%, respectively.
Image Source: Zacks Investment Research
Altria currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.